New Biomarkers in Heart Failure
James L. Januzzi, MD, FACC, FESC, Director, Cardiac ICU and Roman W. DeSanctis Endowed Distinguished Clinical Scholar, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School.
Upon completion of this activity, participants will be able to: Name the biology of ST2 as it pertains to the cardiovascular system. To recall the importance of ST2 for predicting risk across a wide range of cardiac diseases. To formulate a treatment strategy for patients using ST2 measurement.
Disclosure Report: Course Director: Dr. C. A. Sivaram is a consultant and receives honoraria for Medtronic, Inc. Planning Committee Member: Dr. Dwight Reynolds has received grants/research support from Medtronic and Biotronik. He has been a consultant for and has received honoraria from Medtronic. Dr. Faisal Latif has no financial relationships or affiliations to disclose. Course Contact: Kelsey Peters has no financial relationships or affiliations to disclose. Speaker Disclosure: Dr. Januzzi receives grants/research support from Critical Diagnostics, Roche, and BG Medicine. He is also a consultant for Critical Diagnostics, Roche and BG Medicine.
Disclaimer Statement: Statements, opinions and results of studies contained in the program are those of the presenters/authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability. Eery reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.
For more information contact:
Department of Medicine/Cardiovascular Diseases